Brief: Zevra Therapeutics Sells Sdx Portfolio To Commave Therapeutics For $50 Million
16/03/2026 11:38
March 16 (Reuters) - Zevra Therapeutics Inc ZVRA.O: ZEVRA THERAPEUTICS SELLS SDX PORTFOLIO TO COMMAVE THERAPEUTICS FOR $50 MILLION Source text: ID:nGNX1jxzwS Further company coverage: ZVRA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zevra Therapeutics
See all newsU.S. RESEARCH ROUNDUP- Apple, Lennar, Toll Brothers
Rare disease drugmaker Zevra Therapeutics Q1 revenue jumps 78%
Ligand Pharma to acquire fellow biotech royalty rights buyer XOMA for $739 million (updated)
Brief: Zevra Therapeutics Sells Sdx Portfolio To Commave Therapeutics For $50 Million
Zevra Therapeutics beats FY 2025 revenue expectations